BofA/Merrill Lynch analyst Sumant Kulkami reiterated a Buy rating and $14 price target on Momenta Pharmaceuticals (NASDAQ: MNTA) saying they ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE